ArticleClinical ophthalmology (Auckland, N.Z.)2026
Nd:YAG Capsulotomy Rates of Three FineVision Trifocal Intraocular Lens Platform Across Different Platforms: Results from a Multicenter Clinical Registry Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report the neodymium:yttrium-aluminum-garnet (Nd:YAG) laser capsulotomy rates following implantation of three models of the FineVision (BVI Inc. Waltham, USA) diffractive trifocal intraocular lens (IOL). Methods: This was a multicentre, retrospective study including eyes implanted with the FineVision Micro F, FineVision POD/POD FT and the FineVision HP (POD F GF) IOL models after uncomplicated cataract or refractive lens exchange surgeries. The rate of Nd:YAG laser capsulotomy (cumulative incidence) during 1, 3, 5 and 10 years of follow-up were recorded. Results: 190,567 eyes implanted with the three FineVision IOL models were analysed: 170,047 eyes with the FineVision Micro F IOL model, 20,174 eyes with the FineVision POD IOL model, and 346 eyes with the FineVision HP IOL model. Cumulative incidence of Nd:YAG capsulotomy was 3% at 1 year, 6.2% at 3 years, 8.4% at 5 years and 10.9% of eyes at 10 years for the FineVision Micro F IOL model. For the FineVision POD/POD FT IOL model percentages were 6.9% at 1 year, 24.3% at 3 years, and 36.8% of eyes at 5 years. Finally, for the FineVision HP IOL model the percentage at 1 year of follow-up was 6.9% of eyes. Conclusion: Nd:YAG capsulotomies rates varied accordingly to the FineVision IOL model. Differences in IOL material (hydrophilic or hydrophobic) and haptic design (4-closed loops or a double C-loop) could account for these differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.